This study involves a drug called asciminib for people with Chronic Myelogenous Leukemia in Chronic Phase (CML-CP). It is for patients who have either been treated with one previous type of medicine called ATP-binding site TKI (Tyrosine Kinase Inhibitors) and had to stop due to it not working or causing problems, or are newly diagnosed and may have had a short treatment with TKI.
The study has three parts: a screening period up to 28 days, a treatment period up to 104 weeks (2 years), and a 30-day follow-up for safety. During treatment, the medicine dose might be increased based on the patient's response.
- Participants will need to attend multiple study visits over the course of two years.
- There are specific criteria for joining the study, like age and health condition.
- Participants must not have certain heart conditions, must not be pregnant, and must agree to use contraception if of child-bearing potential.
This study aims to find out how effective asciminib is in treating CML-CP and will require informed consent from participants before any procedures are carried out.